

Supplementary Material

Burden of moderate to severe atopic dermatitis in adults from France, Italy and the UK: patient-reported outcomes and treatment patterns

C. Elise Kleyn^a, Sébastien Barbarot^b, Catherine Reed^c, Serena Losi^c, Lill-Brith von Arx^c, Camille Robert^c, Peter Anderson^d, Susanne Grond^c, Antonio Costanzo^{e,f}

^aDermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, The University of Manchester, Manchester, UK

^bCentre Hospitalier Universitaire de Nantes, Service de Dermatologie, Nantes, France

^cEli Lilly and Company, Indianapolis, IN, USA

^dAdelphi Group Products, Macclesfield, Cheshire, UK

^eDermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

^fDermatology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Corresponding author: Catherine Reed

Email: reed_catherine@lilly.com

Supplementary Table 1. Baseline characteristics of patients completing self-completion form (responders) versus patients not completing these forms (non-responders). Data derived from patient record forms completed by physicians

Parameter ^a	France		Italy		UK	
	PSC responder	PSC non-responder	PSC responder	PSC non-responder	PSC responder	PSC non-responder
Number of patients	69	244	129	180	64	224
Age (years)	39.5 (16.4)	36.0 (14.5)	38.1 (14.7)	38.7 (15.6)	37.6 (12.9)	37.2 (17.1)
Sex (% male)	42	58*	50	49	53	49
Ethnicity (% White)	91*	79	99*	91	92*	74
BMI	24.4 (3.4)	23.8 (3.3)	27.6 (30.4)	24.7 (3.7)	26.5 (4.7)	25.9 (4.5)
% employed	61	57	49	51	66*	52
Time since diagnosis (years)	14.5 (15.5)	12.5 (12.8)	9.7** (9.8)	4.8 (8.3)	11.3 (11.7)	14.7 (13.5)
Current BSA affected (%)	19.9 (15.0)	22.4 (17.8)	27.6 (15.7)	23.6 (19.0)	24.7 (17.6)	25.4 (20.4)
Current mean EASI score	9.6 (1.1)	9.4 (0.6)	8.3 (0.5)	7.9 (0.5)	10.6 (1.3)	12.0 (0.6)
Current EASI severity category (%)						
Clear (0–1)	3	4	1	2	2	2
Mild (1.1–7)	54	46	50	55	47	35

Moderate (7.1–21)	30	40	46	39	38	49
Severe (21.1–50)	13	9	3	4	12	14
Very severe (50.1–72)	0	0	0	0	2	0
Currently flaring (%)	53	54	37	35	38	55*
Flared in past 12 months (%)	85	71	54	62	94*	75
Current disease status (%)						
Controlled ^b	41	60*	64	63	48	39
Improving	16	22	22	16	17	24
Stable	25	38*	42	47	31*	15
Uncontrolled ^c	59*	40	36	36	52	61
Changeable	23	14	27	25	41*	28
Deteriorating	36	25	10	11	11	34*

^aMean values (standard deviation) unless indicated otherwise

^bImproving and stable combined

^cChangeable and deteriorating combined

BMI = body mass index; BSA = body surface area; EASI = Eczema Area and Severity Index; PSC = patient self-completion form

*p < 0.05 for the difference between PSC responders and PSC non-responders (Fisher's exact test)

**p < 0.05 for the difference between PSC responders and PSC non-responders (t-test)

Supplementary Table 2. Current conventional systemic therapy by atopic dermatitis severity in France, Italy and the UK. Data derived from patient record forms completed by physicians

Conventional systemic therapy	France			Italy			UK		
	Mod/Sev	Moderate	Severe	Mod/Sev	Moderate	Severe	Mod/Sev	Moderate	Severe
Number of patients	305	237	68	294	247	47	286	239	47
Cyclosporine	25 (8)	13 (5)	12 (18)	36 (12)	34 (14)	2 (4)	17 (6)	10 (4)	7 (15)
Methotrexate	26 (9)	16 (7)	10 (15)	23 (8)	17 (7)	6 (13)	17 (6)	15 (6)	2 (4)
Azathioprine	3 (1)	2 (1)	1 (1)	14 (5)	14 (6)	0 (0)	9 (3)	6 (3)	3 (6)
Mycophenolate mofetil	1 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	9 (3)	9 (4)	0 (0)
Any (all combined)	55 (18)	31 (13)	24 (35)	73 (25)	65 (26)	8 (17)	51 (18)	39 (16)	12 (26)

Data are presented as N or n (%)

Mod/Sev = moderate or severe